Gold mineralized“hybrid nanozyme bomb”for NIR-Ⅱtriggered tumor effective permeation and cocktail therapy
作者机构:Department of PharmaceuticsState Key Laboratory of Nature MedicinesChina Pharmaceutical UniversityNanjing 210009China Wuxi Hequan Pharmaceutical Co.Ltd.Wuxi 214029China Beijing Xinghao Yingsheng Pharmaceutical Co.Ltd.Beijing 102609China School of PharmacyYantai UniversityYantai 264005China School of Pharmaceutical ScienceNanjing Tech UniversityNanjing 211816China
出 版 物:《Chinese Chemical Letters》 (中国化学快报(英文版))
年 卷 期:2024年第35卷第9期
页 面:243-249页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:supported by the National Natural Science Foundation of China(No.81972892)
主 题:Gold mineralized Hybrid nanozyme bomb Starvation therapy Cocktail therapy NSCLC
摘 要:Lung cancer is one of the most common malignant tumors with the fastest increase in the incidence rate and *** after maximum tumor resection assistance with a radiotherapy and chemotherapy combination,the recurrence of non-small cell lung cancer is still *** addition,low targeting efficiency and poor permeability of drug delivery systems strongly affect the therapeutic efficiency of anti-cancer drugs on non-small cell lung *** we designed a gemcitabine(GEM)loaded arginineglycine-aspartic acid-cysteine(RGDc)-modified gold mineralization“hybrid nanozyme bomb(RGTG)to overcome those *** modification improved the active targeting of liposomes to the tumor tissues with the second near-infrared(NIR-Ⅱ)-triggered gold-shell disruption and GEM *** collapsed gold-shell particles with a smaller size could penetrate the tumor solid barrier and act as photothermal therapy(PTT)agents to improve PTT therapy and starvation therapy via generating gluconic acid and reactive oxygen species(ROS).Moreover,the resting reversal effect of gold particles on tumor fibroblasts can achieve accelerating tumor penetration of gold particles and *** to monotherapy,RGTG showed significant improvement in tumor inhibition,with a tumor volume reduction of 83%compared to the control group,which provides a promising tumor treatment platform for non-small cell lung cancer(NSCLC).